Medpace Holdings, Inc. $MEDP Stock: Russell Investments Group Ltd. Lowers Stake

Russell Investments Group Ltd. lessened its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report) by 8.9% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 42,136 shares of the company’s stock after selling 4,113 shares during the quarter. Russell Investments Group Ltd. owned approximately 0.15% of Medpace worth $26,301,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. The Manufacturers Life Insurance Company increased its position in shares of Medpace by 38.9% in the second quarter. The Manufacturers Life Insurance Company now owns 20,043 shares of the company’s stock valued at $10,615,000 after acquiring an additional 5,610 shares during the period. American Capital Management Inc. bought a new position in shares of Medpace during the second quarter valued at about $111,329,000. Focus Partners Advisor Solutions LLC bought a new position in shares of Medpace during the second quarter valued at about $1,685,000. Rice Hall James & Associates LLC bought a new position in shares of Medpace during the second quarter valued at about $28,659,000. Finally, Odyssean LLC purchased a new stake in shares of Medpace during the second quarter worth about $3,369,000. Institutional investors own 77.98% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently issued reports on MEDP shares. Deutsche Bank reissued a “hold” rating and issued a $535.00 target price on shares of Medpace in a research note on Thursday, July 23rd. Mizuho set a $730.00 price target on Medpace in a research report on Friday, October 23rd. Truist Financial upped their price target on Medpace from $609.00 to $633.00 and gave the company a “hold” rating in a research report on Friday, October 23rd. Leerink Partners set a $620.00 price objective on Medpace in a report on Thursday, July 23rd. Finally, TD Cowen lifted their price objective on Medpace from $492.00 to $673.00 and gave the stock a “hold” rating in a research report on Friday, October 23rd. Three equities research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $649.27.

Get Our Latest Stock Report on Medpace

Medpace Trading Up 0.8%

Shares of NASDAQ MEDP opened at $653.09 on Wednesday. Medpace Holdings, Inc. has a 12 month low of $373.00 and a 12 month high of $693.97. The firm has a market capitalization of $18.27 billion, a PE ratio of 36.20, a price-to-earnings-growth ratio of 2.52 and a beta of 1.12. The firm has a fifty day simple moving average of $631.90 and a two-hundred day simple moving average of $534.34.

Medpace (NASDAQ:MEDP – Get Free Report) last posted its earnings results on Wednesday, October 21st. The company reported $4.84 EPS for the quarter, topping the consensus estimate of $4.44 by $0.40. The firm had revenue of $716.00 million during the quarter, compared to analysts’ expectations of $714.47 million. Medpace had a net margin of 18.24% and a return on equity of 99.76%. The company’s quarterly revenue was up 8.5% compared to the same quarter last year. During the same period last year, the company posted $3.86 EPS. On average, sell-side analysts predict that Medpace Holdings, Inc. will post 18.06 earnings per share for the current year.

Insider Transactions at Medpace

In other Medpace news, VP Susan E. Burwig sold 16,060 shares of Medpace stock in a transaction that occurred on Monday, October 26th. The stock was sold at an average price of $677.00, for a total transaction of $10,872,620.00. Following the sale, the vice president directly owned 57,624 shares of the company’s stock, valued at approximately $39,011,448. The trade was a 21.80% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO August J. Troendle sold 49,018 shares of Medpace stock in a transaction that occurred on Tuesday, September 22nd. The shares were sold at an average price of $628.11, for a total value of $30,788,695.98. Following the sale, the chief executive officer directly owned 433,372 shares in the company, valued at approximately $272,205,286.92. The trade was a 10.16% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 278,647 shares of company stock valued at $174,850,299. 20.50% of the stock is owned by insiders.

Medpace Profile

(Free Report)

Medpace Holdings, Inc. is a global contract research organization (CRO) that provides clinical development services to the biotechnology, pharmaceutical and medical device industries. Founded in 1992 and headquartered in Cincinnati, Ohio, the company works with clients developing treatments and medical products across a range of therapeutic areas. Medpace offers services spanning the clinical development process, including clinical trial planning and management, regulatory affairs, clinical laboratory testing, data management, biostatistics, medical writing and pharmacovigilance.

See Also

Institutional Ownership by Quarter for Medpace (NASDAQ:MEDP)

Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.